Italia markets close in 3 hours 58 minutes

Abiomed, Inc. (ABMD)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
330,60+0,63 (+0,19%)
Alla chiusura: 4:00PM EDT

330,80 0,20 (0,06%)
Preborsa: 7:00AM EDT

Accedi per pubblicare un messaggio.
  • V
    Vito
    Unity Biotechnology, Inc.
    don't know if all you speculating about ubx and its science, considered google??
    this is actually based on very old medicine , and many homeopathic remedies that will accomplish positive results. I know for a fact because before investing in ubx I tried it myself., and had instant results in dramatic reduction in inflammation,pain and suffering. I shared the natural diet and treatment protocols with lived ones and they responded positively also!!. I'm not going to go into every aspect of the medical potential of ubx compounds,I'm not a scientist or chemist,, but do your own DD, look it up, try the natural remedies readily available that kill the bad senecent cells for yourselves,, then decide if ubx is onto something? there's also a recent product release by $abmd health(restore cell),, watch the infomercial ,,it's 100% accurate to all other independent research I'd found. That abmd product also has 100%guarrentee so we bought a few bottles and tried it...no complaints. I'm still in UBX, they don't have any patents or the clinical trials to back all this up. I'm not here to promote anything or anyone product,,just shed some light on this info that clearly not many are aware of. I've been following ubx since it was $3 and clearly the people involved in this company are still heavily invested themselves.
    beware the shorts trying to spout negatives so you sell and they profit on their put options.. it's clear who they are from their comments. glta
  • V
    Vik
    Abiomed: Upside That Will Get Your Heart Pumping $ABMD
    https://seekingalpha.com/article/4257052
    Disruptive Medical device company specializing in heart pumps for high risk heart surgery. Low current penetration rates in current and attractive product featu
    Disruptive Medical device company specializing in heart pumps for high risk heart surgery. Low current penetration rates in current and attractive product featu
    seekingalpha.com
  • V
    Vik
    Abiomed: Keeps The Heart And Your Portfolio Pumping $ABMD https://seekingalpha.com/article/4254611
    Abiomed offers a niche product to a market that is experiencing phenomenal growth metrics. Its product is an inelastic good, giving the company flexibility in p
    Abiomed offers a niche product to a market that is experiencing phenomenal growth metrics. Its product is an inelastic good, giving the company flexibility in p
    seekingalpha.com
  • t
    tom
    $ABMD conversation
    Look what happened last time you made this call on Nov. 1 at the same price $330. Shot up to $426 in 6 days. Wonder what will happen this time...............

    Presifdsdsf 13 days ago
    $ABMD conversation
    MASSIVE DROP COMING UP ON EARNINGS!! LOOK WAHT HAPPENED TO ISRG!!! SHORT NOW
  • K
    Kevin
    $ABMD conversation
    Why Abiomed Stock Is Jumping Today marketwirenews.com/news-rel... $ABMD News Article
  • T
    Tommy
    $ABMD conversation
    Abiomed: Straight From The Heart https://seekingalpha.com/article/4325506?source=ansh $ABMD
    Abiomed’s stock got hammered despite its Q4 2019 earnings beating analyst estimates. Studies conducted by the American Heart Association (AHA) and Journal of th
    Abiomed’s stock got hammered despite its Q4 2019 earnings beating analyst estimates. Studies conducted by the American Heart Association (AHA) and Journal of th
    seekingalpha.com
  • E
    Emmanuel
    $QD conversation
    $ABMD Abiomed to Present at the 38th Annual J.P. Morgan Healthcare Conference https://blueequity.io/r/78650/MA-ABIOMED
    We’re on a mission to democratize financial analysis.
    We’re on a mission to democratize financial analysis.
    blueequity.io
  • J
    Jeff
    Been with Abiomed since artificial heart always did well , I feel it's a $150 stock and I think some bigs buyers are looking at it to acquire
  • n
    ny
    $ABMD conversation
    What's with the drop?
  • T
    Tina Lerch
    $ABMD conversation
    Earnings reported 2 cents above the high estimate for EPS for Q3 in press release after close.
    Official earnings release on the 26th. Preliminary results are being provided in advance of the Company's presentation at the 35th Annual J.P. Morgan Healthcare Conference.
  • J
    Jeff
    I'll reiterate my opinion it's a $150-$170 stock
  • S
    Shooter MacGavin
    $ABMD conversation
    Whoa! What news came out about $ABMD? It was a steady climber the last month or so and blamo! Anyone know what's going on?
  • m
    mac
    I'm thinking a beat on earnings before bell,just hope that means nice pop
  • M
    Michael
    $ABMD conversation
    ......apparently Abbott labs suspended enrollment of it's HeartMate shield therefore halting sales in Europe..... Jeffries now has a price target of 135
  • R
    Rxpert
    $ONCE conversation
    This stock will drop like a rock when insurers decide to cover only one eye. One-eyed blind is still seeing. $ABMD has a better risk/reward ratio, and a population that continues to age.
  • J
    Jeff
    $ABMD conversation
    With a great growth report with above all in all categories its tanking, I am a ABMD be leaver and its a $150 stock but, #$%$
  • B
    Barton
    $ABMD conversation
    No idea but I have been on the MB's here for over 20 years now and I am leaving immediately. Good bye Yahoofinance,com
  • J
    Jeff
    Higher highs and higher lows, I line the ladder effect the way it's climbing I'm saying as I always did it a $150 stock or a buy out a buy out at higher
  • D
    David
    $ABMD conversation
    Annual report is interesting.
  • J
    Joey Tortellini
    $ABMD conversation
    I find it interesting that this past quarter was their best sequential revenue growth ever at 11pct. I guess part of it is due to Q2 not being as strong. Looks like sequential revenue growth for next quarter is coming in at an estimated 6pct. I use YOY obviously but still like to understand sequential too.
    Hope we climb higher from here...seems the long-term story is in tact.